(Q44276659)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

0 references

0 references

1 reference

inflammatory bowel diseases

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

9

Shomron Ben-Horin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

8

Rami Eliakim

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Bella Ungar

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Yehuda Chowers

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Miri Yavzori

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Orit Picard

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Ella Fudim

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Ofir Har-Noy

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

ABIRISK consortium

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

language of work or name

English

0 references

publication date

16 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

63

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

1258-1264

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Therapeutic drug monitoring of biologics for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Assessing response and loss of response to biological therapies in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

A simple index of Crohn's-disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Review article: loss of response to anti-TNF treatments in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Predicting the response to infliximab from trough serum levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305259

10.1136/GUTJNL-2013-305259

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24041539%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference